BIOPHYTIS ON THE STOCK MARKET Biophytis has been listed on the market Euronext Growth Paris since July 13, 2015 ISIN FR001400OLP5 Ticker: ALBPS Type of listing: continuous Total number of shares at 31/12/2024: 7,342,9711 ADR = 10 sharesNumber of voting rights at 31/12/2024: 7,373,277 Eligible for PEA and PEA-PME equity saving plans Analyst Coverage February,…
DetailsAbout Age-related Macular Degeneration Age-Related Macular Degeneration (AMD) affects the central part of the retina, known as the macula, which is responsible for central vision and its sharpness. AMD is one of the leading causes of irreversible vision loss and blindness in people over the age of 50 worldwide. There are two types of AMD:…
DetailsSARCOPENIA: SARA CLINICAL PROGRAMME 1. An age-related disease with no drug treatment Sarcopenia is a disease characterised by a progressive and widespread loss of skeletal muscle mass and function, leading to muscle weakness, and is related to falls, disability, a significant reduction in quality of life and death. Sarcopenia affects between 10% and 16%…
DetailsLegal notice SITE PUBLISHER BIOPHYTIS14 avenue de l’Opéra75001 Paris CNIL In accordance with the law No. 78-17 dated 6 January 1978 relating to information technology, files and freedoms, natural persons have a right of access and correction in respect of personal data concerning them. This right can be exercised with the management. HOSTING Le site…
DetailsFrance BIOPHYTISSorbonne UniversitéBâtiment A 4e étage4 place Jussieu – 75252 Paris Cedex 05Tél. +33 1 44 27 23 00 USA BIOPHYTISc/o NGIN210 Broadway, Suite #201Cambridge, MA 02139
DetailsStanislas VEILLET – Chairman Stanislas Veillet set up Biophytis in September 2006. He had previously held a number of posts in the fields of medical research, nutrition and functional foods, in particular with Danone, Pharmacia-Monsanto and Cargill. Stanislas has a doctorate in genetics, graduated in engineering from Agro ParisTech and is author of a dozen…
DetailsPROFESSOR ROGER A. FIELDING Dr. Fielding is currently a Professor at the Friedman School of Nutrition Science and Policy at Tufts University. He is also the Director of Human Studies at the Jean Mayer USDA Human Nutrition Research Center on Aging, a Lecturer on Physical Medicine and Rehabilitation at Harvard Medical School’s Department of Physical…
DetailsStanislas VEILLET – PhD – Chairman – CEO Stanislas Veillet created Biophytis in September 2006. He previously held a number of positions in the fields of medical research, nutrition and functional foods, in particular with Danone, Pharmacia-Monsanto and Cargill. Stanislas has a doctorate in genetics, graduated in engineering from AgroParisTech and has authored a dozen…
DetailsOur second drug candidate, Macuneos (BIO201), is an orally administered small molecule for the treatment of diseases of the retina. Based on preclinical studies, we believe Macuneos (BIO201) stimulates biological resilience through non-canonical activation of the transrepressive activity of PPARs and may protect the retina against phototoxic damage caused by A2E (a by-product of the…
DetailsOur lead drug candidate, Ruvembri, is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, we believe Ruvembri stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity…
Details